Skip to main content

Table 2 Clinical trials using anti-platelet and anti-coagulation therapy

From: Platelets, coagulation and fibrinolysis in breast cancer progression

Drug Target Study description Percentage of patients with breast cancer Results Breast cancer-specific results Reference
Aspirin Platelets Prospective observational study 100% Decreased distant recurrence and mortality 43% risk reduction in distant recurrence and 74% risk reduction in mortality [41]
Benoral Platelets Double-blind 100% No survival benefit   [87]
Dalteparin Coagulation Randomized clinical trial in advanced-stage III and IV solid tumors 17% No survival benefit with advanced malignancy Improved survival in subgroup of patients with better prognosis Unknown [80]
   Randomized double-blind controlled study changed to open-labeled clinical trial 10.8% No survival benefit with advanced cancer Unknown [81]
Nadroparin Coagulation Randomized clinical trial in locally advanced or metastasized solid tumors without any concomitant chemotherapy or radiation treatment 16.5% Improved survival (especially more pronounced in patients with estimated life expectancy of 6 months or greater) Hazard ratio of 0.78 [82]
   Randomized clinical trial 14% No survival benefit Unknown [83]
Warfarin Coagulation Double-blind randomized trial 100% No detectable survival benefit but decreased relative risk of venous thromboembolism by 85%   [84]